

**Extraordinary Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
27 May 2021
Virtual meeting
Agenda**

Thursday, 27 May 2021

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
11:00	Closed SAGE meeting	Preparation of the session.	30 min.
11:30	Break	Break	30 min.
12:00	Opening and welcome Welcome: A. Cravioto. SAGE Chair. 5 min.	Opening of the Plenary Meeting	5 min.
12:05	COVID-19 vaccine - part 1 Update on recent developments including on COVAX. K. O'BRIEN. Director Immunization Vaccines and Biologicals (IVB). 10 min. Introduction and objective setting. H. NOHYNEK. SAGE Member. 10 min. Presentation on recent data on BNT162b2 use in the context of variants of concern, booster studies and on the results of the phase 3 trial in adolescents 12-15 years of age using BNT162b2 Pfizer/ BioNtech SARS-CoV-2 vaccine. COMPANY PRESENTATION. 20 min. Discussion on paediatric age indication. 20 min. Cross-cutting issues for mRNA vaccines. 60 min. <ul style="list-style-type: none"> Presentation on safety of mRNA vaccines. (GACVS member) Questions. 10 min. <ul style="list-style-type: none"> Vaccination with mRNA vaccines during pregnancy and lactation. (S. Omer) Presentation of vaccine effectiveness, including against variants of concern. (M. Patel) Vaccination following previous of SARS-CoV-2 infection. (M. Patel) Deferral second dose. (M. Ramsay, A. Finn, N. Grassly) Questions. 20 min. Discussion on update of recommendation on the use of BNT162b2 Pfizer/ BioNtech and mRNA-1273 Moderna vaccines. H. NOHYNEK. SAGE Member. 30 min.	FOR RECOMMENDATION Purpose: Update on vaccine registration, vaccine introduction status and COVAX. Presentation of clinical data. Outline of ongoing and planned studies. Presentation of data on various aspects related to available SARS-CoV-2 vaccines. Based on the presented evidences, presentation of draft updated recommendations on the use of BNT162b2 Pfizer/ BioNtech and mRNA-1273 Moderna vaccines against COVID-19.	2h 55 min.

15:00	Break	Break	25 min.
15:25	COVID-19 vaccine – part 2 Presentation on Thrombosis with Thrombocytopenia Syndrome (TTS) associated with the Janssen Ad26.COV2.S vaccine. Member of GACVS. 15 min. Discussion: 15 minutes Presentation of the updates Ad26.COV2.S recommendations. H. NOHYNEK. SAGE Member. 5 min.	FOR RECOMMENDATION Presentation of data on a very rare syndrome of blood clotting combined with low platelet counts reported following vaccination with the Ad26.COV2.S vaccine. Based on the presented evidences, presentation of draft updated recommendations on the use of Ad26.COV2.S vaccine against COVID-19.	35 min.
16:00	End of the meeting		